Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Cancer Chemotherapy and Pharmacology
|
September 22, 2007
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
Howard H Bailey, Steven Attia, Richard R Love, et al.
Gynecologic Oncology
|
January 30, 2007
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
David M Kushner, Joseph P Connor, Federico Sanchez, et al.
Cancer Chemotherapy and Pharmacology
|
November 27, 2002
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
James P Thomas, Kendra D Tutsch, James F Cleary, et al.
Cancer Investigation
|
March 23, 2005
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study
Brad S Kahl, Howard H Bailey, Eileen P Smith, et al.
Leukemia & Lymphoma
|
August 26, 2011
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network
Vaishalee P Kenkre, Walter L Long, Jens C Eickhoff, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 23, 2015
Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
Carol J Fabian, Bruce F Kimler, Carola M Zalles, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 20, 2014
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer
Jill M Kolesar, Marcia Pomplun, Tom Havighurst, et al.
Cancer Chemotherapy and Pharmacology
|
June 19, 2004
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
Howard H Bailey, George Wilding, Kendra D Tutsch, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2013
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
Jill M Kolesar, Anne M Traynor, Kyle D Holen, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy
Jason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Cancer Chemotherapy and Pharmacology
|
September 22, 2007
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
Howard H Bailey, Steven Attia, Richard R Love, et al.
Gynecologic Oncology
|
January 30, 2007
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
David M Kushner, Joseph P Connor, Federico Sanchez, et al.
Cancer Chemotherapy and Pharmacology
|
November 27, 2002
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
James P Thomas, Kendra D Tutsch, James F Cleary, et al.
Cancer Investigation
|
March 23, 2005
Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study
Brad S Kahl, Howard H Bailey, Eileen P Smith, et al.
Leukemia & Lymphoma
|
August 26, 2011
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network
Vaishalee P Kenkre, Walter L Long, Jens C Eickhoff, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 23, 2015
Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer
Carol J Fabian, Bruce F Kimler, Carola M Zalles, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 20, 2014
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer
Jill M Kolesar, Marcia Pomplun, Tom Havighurst, et al.
Cancer Chemotherapy and Pharmacology
|
June 19, 2004
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
Howard H Bailey, George Wilding, Kendra D Tutsch, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2013
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
Jill M Kolesar, Anne M Traynor, Kyle D Holen, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy
Jason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Page
of 6